Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label … X Forns, SS Lee, J Valdes, S Lens, R Ghalib, H Aguilar, F Felizarta, ... The Lancet infectious diseases 17 (10), 1062-1068, 2017 | 422 | 2017 |
A randomized clinical trial of endometrial perfusion with granulocyte colony-stimulating factor in in vitro fertilization cycles: impact on endometrial thickness and clinical … DH Barad, Y Yu, VA Kushnir, A Shohat-Tal, E Lazzaroni, HJ Lee, ... Fertility and sterility 101 (3), 710-715, 2014 | 191 | 2014 |
Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer CJ Hoimes, TW Flaig, MI Milowsky, TW Friedlander, MA Bilen, S Gupta, ... Journal of clinical oncology 41 (1), 22-31, 2023 | 167 | 2023 |
Elevated pre-operative serum peptides for collagen I and III synthesis result in post-surgical atrial fibrillation MF Swartz, GW Fink, MF Sarwar, GL Hicks, Y Yu, R Hu, CJ Lutz, SM Taffet, ... Journal of the American College of Cardiology 60 (18), 1799-1806, 2012 | 110 | 2012 |
Oocyte Scoring Enhances Embryo-Scoring in Predicting Pregnancy Chances with IVF Where It Counts Most E Lazzaroni-Tealdi, DH Barad, DF Albertini, Y Yu, VA Kushnir, H Russell, ... PloS one 10 (12), e0143632, 2015 | 100 | 2015 |
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis P Lampertico, JA Carrión, M Curry, J Turnes, M Cornberg, F Negro, ... Journal of hepatology 72 (6), 1112-1121, 2020 | 88 | 2020 |
Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer PH O'Donnell, MI Milowsky, DP Petrylak, CJ Hoimes, TW Flaig, N Mar, ... Journal of Clinical Oncology 41 (25), 4107-4117, 2023 | 69 | 2023 |
Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open … T Asselah, C Hézode, RB Qaqish, M ElKhashab, T Hassanein, ... The Lancet Gastroenterology & Hepatology 1 (1), 25-35, 2016 | 68 | 2016 |
LBA73 Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible … JE Rosenberg, M Milowsky, C Ramamurthy, N Mar, RR McKay, ... Annals of Oncology 33, S1441, 2022 | 52 | 2022 |
Study EV-103: Update on durability results and long term outcome of enfortumab vedotin+ pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC). TW Friedlander, MI Milowsky, MA Bilen, S Srinivas, RR McKay, TW Flaig, ... Journal of Clinical Oncology 39 (15_suppl), 4528-4528, 2021 | 46 | 2021 |
Partial linear single index models with distortion measurement errors J Zhang, Y Yu, LX Zhu, H Liang Annals of the Institute of Statistical Mathematics 65, 237-267, 2013 | 35 | 2013 |
Anti‐mullerian hormone levels decline with the presence of antiphospholipid antibodies M Vega, DH Barad, Y Yu, SK Darmon, A Weghofer, VA Kushnir, ... American Journal of Reproductive Immunology 76 (4), 333-337, 2016 | 34 | 2016 |
Early decline in functional ovarian reserve in young women with low (CGG n< 26) FMR1 gene alleles N Gleicher, Y Yu, E Himaya, DH Barad, A Weghofer, YG Wu, DF Albertini, ... Translational Research 166 (5), 502-507. e2, 2015 | 33 | 2015 |
Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are … DP Petrylak, TW Flaig, N Mar, TS Gourdin, S Srinivas, JE Rosenberg, ... Journal of Clinical Oncology 40 (6_suppl), 435-435, 2022 | 30 | 2022 |
Utilizing FMR1 gene mutations as predictors of treatment success in human in vitro fertilization VA Kushnir, Y Yu, DH Barad, A Weghofer, E Himaya, HJ Lee, YG Wu, ... PLoS One 9 (7), e102274, 2014 | 23 | 2014 |
Estimation and variable selection in partial linear single index models with error-prone linear covariates J Zhang, X Wang, Y Yu, Y Gai Statistics 48 (5), 1048-1070, 2014 | 21 | 2014 |
Profiled adaptive Elastic-Net procedure for partially linear models with high-dimensional covariates B Chen, Y Yu, H Zou, H Liang Journal of Statistical Planning and Inference 142 (7), 1733-1745, 2012 | 17 | 2012 |
Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin+ pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial … S Gupta, JE Rosenberg, RR McKay, TW Flaig, DP Petrylak, CJ Hoimes, ... Journal of Clinical Oncology 41 (16_suppl), 4505-4505, 2023 | 16 | 2023 |
Estimation and hypothesis test on partial linear models with additive distortion measurement errors J Zhang, Y Zhou, B Lin, Y Yu Computational Statistics & Data Analysis 112, 114-128, 2017 | 15 | 2017 |
Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial … PH O'Donnell, JE Rosenberg, CJ Hoimes, DP Petrylak, MI Milowsky, ... Journal of Clinical Oncology 41 (6_suppl), 499-499, 2023 | 12 | 2023 |